Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial

Abstract PIK3CA is mutated in ~15% of colorectal cancers (CRC). PI3K regulates immunity, inhibition potentially enhances anti-tumor immunity. We launched a phase 1/2 trial of copanlisib (PIK3CA inhibitor) and nivolumab (anti-PD-1) in metastatic microsatellite stable CRC (NCT03711058): Cohort A: PIK3...

Descripció completa

Dades bibliogràfiques

Autors principals:	Eric S. Christenson, Jeremiah A. Wala, Rose Parkinson, Natalie B. Collins, Christopher Jakubowski, Jia-Ren Lin, Kristin Qian, Jiayun Lu, Hao Wang, Won Jin Ho, Sabrina Chan, Ewa Kulikowicz, Rachel Klein, Yvette Cetasaan, Emma Johnson, Maureen Berg, Jeffrey A. Meyerhardt, Dung T. Le, Benjamin L. Schlechter, Ilene Browner, Lei Zheng, Harshabad Singh, Ross Donehower, Elizabeth M. Jaffee, Peter K. Sorger, Marios Giannakis, Nilofer Azad
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2026-07-01
Col·lecció:	Nature Communications
Accés en línia:	https://doi.org/10.1038/s41467-026-72985-6
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!